Sek Kathiresan, Verve Therapeutics CEO
With first base editing clinical trial underway, Verve discloses second cardiovascular disease program
In July, Verve Therapeutics dosed its first patient with a base editing therapy for heterozygous familial hypercholesterolemia (FH), marking the first time base editing …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
